about
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Emerging drugs for T-cell lymphoma.Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Romidepsin for peripheral T-cell lymphoma.
@en
type
label
Romidepsin for peripheral T-cell lymphoma.
@en
prefLabel
Romidepsin for peripheral T-cell lymphoma.
@en
P2093
P2860
P1476
Romidepsin for peripheral T-cell lymphoma.
@en
P2093
H Miles Prince
Michael Dickinson
P2860
P304
P356
10.1586/17474086.2013.814833
P577
2013-08-01T00:00:00Z